UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Amendment No. __)
Under the Securities Exchange Act of 1934
THORATEC CORPORATION
----------------------------
(Name of Issuer)
Common Stock, no par value per share
------------------------------------
(Title of Class of Securities)
885175 30 7
------------
(CUSIP Number)
Hardin Holmes
Ireland, Stapleton, Pryor & Pascoe, P.C.
1675 Broadway, 26th Floor, Denver, Colorado 80202
303.623.2700
-------------------------------------
(Name, Address and Telephone Number of
Person Authorized to Receive Notices
and Communications)
November 6, 2001
--------------------------------------
(Date of Event which Requires Filing of
this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box. [ ]
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See ss.240.13d-7(b) for other
parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be “filed” for the purpose of Section 18 of the Securities Exchange
Act of 1934 (“Act”) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
CUSIP No. 885175 30 7
1. Name of Reporting Person. S.S. or I.R.S. Identification No. of above
persons (entities only)
Gambro, Inc., f/k/a COBE Laboratories, Inc.
................................................................................
2. Check the Appropriate Box if a Member of a Group
(a)
(b)
................................................................................
3. SEC Use Only
................................................................................
4. Source of Funds:
................................................................................
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items
2(d) or 2(e)
................................................................................
6. Citizenship or Place of Organization:
State of Colorado
................................................................................
Number of 7. Sole Voting Power: 1,411,000
Shares ................................................................
Beneficially 8. Shared Voting Power: -0-
Owned by ................................................................
Each 9. Sole Dispositive Power: 1,411,000
Reporting ................................................................
Person 10. Shared Dispositive Power: -0-
With ................................................................
11. Aggregate Amount Beneficially Owned by Each Reporting Person:
1,411,000
................................................................................
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares
................................................................................
13. Percent of Class Represented by Amount in Row (11):
2.6%
................................................................................
14. Type of Reporting Person
CO
................................................................................
Item 2. Identity and Background. This statement is being filed by Gambro, Inc., f/k/a COBE Laboratories, Inc., a Colorado corporation (the “Reporting Person”). The Reporting Person’s principal office is located at 10810 W. Collins Avenue, Lakewood, CO 80215. The purpose of this Amendment is to reflect the reduction of the interest of the Reporting Person in the common stock of the Issuer to less than 5% of the outstanding shares, as a result of recent sales of shares by the Reporting Person.
Item 5. Interest in the Securities of the Issuer.
Item 5 is hereby amended and restated in its entirety as follows:
On October 1, 2001, the Reporting Person owned 3,133,076 shares of the outstanding Common Stock of the Issuer, representing 5.7% of the 55,140,000 shares outstanding. As of November 6, 2001 the Reporting Person owned 1,411,000 shares of Common Stock of the Issuer, which represents 2.6%, as a result of the following open market sales with respect to the Common Stock:
Date Amount Price Per Share
---- ------ ---------------
10/08/01 6,000 18.75
10/09/01 25,000 18.0684
10/10/01 100,000 18.0375
10/11/01 4,100 18.15
10/11/01 90,900 18.328
10/11/01 55,000 18.328
10/12/01 80,000 18.5
10/15/01 30,000 18.5
10/16/01 100,000 18.6875
10/17/01 5,000 19.2
10/18/01 25,000 19.0
10/18/01 25,000 18.75
10/18/01 15,000 19.1133
10/19/01 20,000 20.5
10/19/01 100,000 20.0
10/19/01 50,000 19.25
10/19/01 35,000 21.0
10/22/01 25,000 20.75
10/23/01 80,000 20.56255
10/24/01 40,000 19.25
10/24/01 50,000 19.0
10/24/01 100,000 18.25
10/25/01 50,000 19.5
10/25/01 100,000 19.0
10/26/01 40,000 19.5
10/31/01 30,000 19.5
10/31/01 50,000 19.21
10/31/01 50,000 19.2
11/01/01 27,500 19.57277
11/05/01 2,500 19.85
After reasonable inquiry and to my best knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
GAMBRO, INC.
November 9, 2001 By: /s/ Kevin Smith
---------------- -----------------------------------
Date Kevin Smith, President